Badr Ratnakaran, MBBS, highlights the growing loneliness epidemic and emphasizes its severe impact on mental and physical health at the 2025 APA Annual Meeting.

It seems there is no text provided for summarization. Please share the content you'd like summarized, and I'll be happy to help!

Promising results from a phase 2 study of CPL'36, a novel PDE10A inhibitor, for acute schizophrenia exacerbation was presented at the APA annual meeting.

Research from the 2025 APA Annual Meeting reveals a strong link between borderline personality disorder and problematic internet use, highlighting impulsivity and compulsivity in affected individuals.

Attendees at the 2025 APA Annual Meeting are excited to connect with peers and experts, exploring lifestyle medicine and networking opportunities for career growth.

Mental health professionals recognize the profound impact of climate change on anxiety, depression, and overall well-being, urging proactive support for affected patients, says one APA attendee.

Can GLP-1 agonists support patients on antipsychotics? Amir Meftah, MD, and colleagues explore its use.

Angelo Chaia, MD, explores the impact of long-acting injectables on patients with severe mental illness and substance use disorders at the 2025 APA Annual Meeting.

At the APA Annual Meeting, Dana Hilt, MD, PhD, explores the notion of precision psychiatry in depression treatment.

Amir Meftah, MD, discusses the possibility of GLP-1s for addressing metabolic issues associated with antipsychotics.

Dana Hilt, MD, PhD, discusses data on Xanamem’s impact on cortisol and its potential use in MDD at the APA Annual Meeting.

What should you know about the lesser known psychedelics? Clinical insights from Jacob Perlson, MD, MPH, at the APA Annual Meeting.

Our board members are presenting at this year's APA Annual Meeting. Be sure to check out their sessions!

The Osheroff v. Chestnut Lodge case had a transformative impact on psychiatric practices and the evolving relationship between science and religion.

New analyses reveal valbenazine (Ingrezza) significantly enhances quality of life and functional outcomes for patients with tardive dyskinesia, supporting its long-term efficacy.

Psychiatrists can leverage media to reshape mental health narratives, combat misinformation, and engage with the public, in a way that fosters open conversations and reduces stigma.

"I feel I’ve known him a long time, familiar as red in the maple outside or the smell of leather on my father’s skin..."

Etkin describes precision psychiatry data for MDD presented at the Society for Biological Psychiatry Annual Meeting.

Mental health professionals should navigate media engagement by upholding ethical standards, ensuring informed consent, and combating misinformation to promote public awareness.

Uncertainty fuels anxiety, yet knowing outcomes—even grim ones—can bring relief.

Check out this year's Gerald F. Berlin Prize winner!

Let's take another look at the connection between motherhood and mental health.

Badr Ratnakaran, MBBS, Psychiatric Times' new Climate Change Section Editor, explores the intersection of climate change and mental health, highlighting the urgent need for awareness and support in clinical practice.